Main Uses and Benefits of Butylscopolamine and Scopolamine

Butylscopolamine and scopolamine are medications belonging to the antispasmodic and anticholinergic classes. While they share a similar chemical origin, they are utilized for different primary indications based on how they interact with the body.

Relief of Gastrointestinal Spasms

Butylscopolamine is primarily used to alleviate cramps and spasms in the digestive system. It works by relaxing the smooth muscles in the walls of the stomach, intestines, and biliary tract. By reducing the intensity of these contractions, it helps to manage discomfort associated with several conditions:

• Abdominal Cramping: It provides relief for general functional spasms of the gastrointestinal tract.
• Irritable Bowel Syndrome (IBS): It is frequently used to manage the acute bouts of painful abdominal cramping often experienced by individuals with IBS.
• Biliary Colic: It can help relax the bile ducts to ease the pain caused by spasms in the gallbladder area.

Management of Genitourinary Spasms

The muscle-relaxing properties of butylscopolamine also extend to the genitourinary system. It is used to reduce spasms in the bladder and the urinary tract, which may occur during certain diagnostic procedures or as a result of kidney stones (renal colic).

Prevention of Motion Sickness

In contrast to the digestive focus of butylscopolamine, scopolamine (often administered via a transdermal patch) is widely used for its effects on the central nervous system to prevent nausea and vomiting.

• Motion Sickness: Scopolamine works by blocking the transmission of signals in the inner ear that trigger the vomiting center in the brain during travel by sea, air, or car.
• Postoperative Nausea: In some clinical settings, it is used to manage nausea following surgery and anesthesia.

Secretion Control and End-of-Life Care

Both forms of the medication can be used to reduce the production of bodily secretions.

• Excessive Salivation: It can help reduce overproduction of saliva or respiratory secretions.
• Palliative Care: In end-of-life care, these medications are sometimes used to manage "death rattle," a term for the noisy breathing caused by the accumulation of secretions in the airway when a patient is no longer able to clear them.

Regulatory References

1. Medicines and Healthcare Products Regulatory Agency (MHRA)

Who Can and Cannot Use Butylscopolamine/Scopolamine? (Eligibility Summary)

Eligibility for Butylscopolamine (Hyoscine Butylbromide) and Scopolamine (Hyoscine) is strictly defined by regulatory contraindications and warnings, prohibiting use in specific populations or conditions.

Absolute Non-Eligibility (Contraindications)

The medicine is formally contraindicated and must not be used by patients with:

• Hypersensitivity to the drug or related compounds.
• Myasthenia gravis.
• Untreated angle-closure glaucoma.
• Gastrointestinal or Urinary Obstructions (e.g., paralytic ileus, megacolon, mechanical stenosis).
• Tachycardia (for parenteral injection).

Age and Physiological Restrictions

Conditional Use (Caution Required)

Use requires caution and monitoring in the elderly, patients with impaired renal or hepatic function, or those with pre-existing cardiac conditions (e.g., coronary heart disease) or a history of seizures.

Butylscopolamine/Scopolamine Interactions with other medicines and products

This section outlines documented interactions between butylscopolamine and other medicines based strictly on regulatory and authoritative health information.

Potential for Enhanced Anticholinergic Effects

The co-administration of butylscopolamine with other medicines that possess anticholinergic properties can lead to an increase in these effects. Due to this potential for enhanced action, co-administration with other anticholinergic drugs should be avoided.

Medicines documented to have the potential to potentiate anticholinergic effects include:

• Antidepressants (Tricyclic and Tetracyclic classes)
• Antihistamines
• Antipsychotics (such as phenothiazines, butyrophenones, and clozapine)
• Quinidine
• Amantadine
• Disopyramide

Functional Antagonism and Other Effects

Butylscopolamine's effects on gastrointestinal motility can be opposed by dopamine antagonists, such as Metoclopramide, which promote movement. Concomitant use with these agents may result in a reduction of their effect.

Caution is also required when butylscopolamine is co-administered with beta-agonists. This combination may lead to the potentiation of tachycardic effects (increased heart rate). Regulatory sources indicate that these combinations warrant careful monitoring.

Butylscopolamine/Scopolamine functions as a competitive antagonist within the autonomic nervous system. Its primary action involves interfering with the neurotransmitter acetylcholine at peripheral muscarinic acetylcholine receptors (mAChRs), notably the M3 subtype, which are prevalent on smooth muscle cells and exocrine glands throughout the gastrointestinal, biliary, and genitourinary tracts. The drug binds directly to these receptors, thereby preventing acetylcholine from initiating the normal cholinergic signaling cascade. This blockade on postganglionic parasympathetic nerve endings suppresses excitatory action. The resulting mechanistic cascade is a direct reduction in smooth muscle tone, leading to a spasmolytic effect, and a simultaneous inhibition of glandular secretion. This mechanism modulates the activity of visceral smooth muscle, resulting in decreased contractile force within the targeted systems.

Butylscopolamine (Hyoscine butylbromide) administration is defined by two routes: oral for tablets and parenteral (Intravenous, Intramuscular, or Subcutaneous) for the solution for injection. The selection of the route is based on the necessity for acute, supervised relief versus non-acute, self-administered use.

Dosing and Frequency

For adults, the oral dose is typically 10 mg to 20 mg (one to two tablets), which is administered in a divided regimen three to five times per day. The tablets must be swallowed whole with water and should not be crushed or chewed. For acute episodes requiring rapid action, the parenteral dose is 20 mg via slow injection and may be repeated after a minimum interval of 30 minutes, provided the maximum adult daily dose of 100 mg is not exceeded. The solution for injection may be diluted with 0.9% sodium chloride or 5% glucose prior to administration.

Population and Procedural Constraints

Usage constraints specify that the medication is intended for short-term, intermittent use and should not be taken on a continuous daily basis without medical investigation. There are specific procedural rules for administration: the Intramuscular (IM) route must be avoided in patients receiving anticoagulant therapy, requiring the use of the IV or SC routes instead. Dose adjustments are also documented for children. Children aged 6 to 12 years are typically administered a 10 mg oral dose three times daily, while infants may receive a weight-based parenteral dose (e.g., up to 1.2 mg/kg per day) in severe cases.

Research evidence / Overview of Studies for Butylscopolamine/Scopolamine

Evidence for Use in Abdominal Cramps and General Spasms

Research examined Butylscopolamine in studies focused on conditions characterized by fluctuating or episodic manifestations, such as general gastrointestinal (GI) spasms. These investigations, which often included short-term Randomized Controlled Trials (RCTs) and reviews that consolidated existing data, explored how symptoms change over time and focused on patient-reported outcomes describing perceived discomfort and variability in pain intensity. Studies report how symptoms evolved in the observed populations; data show patterns related to changes in average pain scores measured over defined, short-term time intervals.

Evidence for Use in Acute Colic Pain (Renal and Biliary)

Studies focusing on acute colic pain, which are conditions associated with acute or disruptive episodes, typically involved placebo-controlled RCTs conducted during periods of increased symptom activity. Research examined temporary physiological imbalance related to spasm and monitored outcomes describing episodic or acute changes. Key measurements focused on outcomes related to physical discomfort. Findings describe patterns observed in the studies, including measurements of time until subsequent pain scores were recorded.

Long-Term Studies and Durability of Effect

Across all indications, there is limited information for long-term outcomes and the durability of response. Follow-up durations were often limited to the acute or short-term phase of symptom management. Therefore, long-term effects on chronic, recurring conditions characterized by fluctuating or episodic manifestations are not fully established. Research is ongoing to better understand sustained changes over time and to provide clearer context for conditions presenting with cycles of stability and flare-ups.

Evidence in Special Populations

Evidence in special populations, such as children and pregnant or breastfeeding women, was evaluated in limited research. Research in these groups primarily involved case series and retrospective reviews, meaning sample sizes were modest. Studies monitored safety profiles and recorded outcomes related to systemic or functional imbalance. Long-term effects regarding functional outcomes in pediatric populations are not fully established, and certainty remains low due to the limited scope and non-randomized nature of the available research.

Key Studies & References

1. Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine-n-butylbromide (Buscopan)
2. Public Assessment Report Scientific discussion Butylscopolamine bromide RIA 10 mg film-coated tablets (hyoscine butylbromide)

Common questions about Butylscopolamine/Scopolamine (FAQ)

Q: What types of abdominal or visceral pain is Butylscopolamine typically approved for?

A: Butylscopolamine is approved for the relief of abdominal pain associated with spasms, which are painful, involuntary muscle contractions. Official information indicates its use to treat symptoms related to gastrointestinal spasm, biliary colic (gallstone pain), and renal colic (kidney stone pain).

Q: What are the most commonly reported side effects of Butylscopolamine?

A: The highest frequency adverse reactions listed in regulatory documents include dry mouth, dizziness, blurred vision, constipation, and nausea. Other peripheral effects, such as an increased heart rate (tachycardia) and decreased sweating, are also documented in official information.

Q: Does Butylscopolamine usually cause sleepiness or drowsiness?

A: Sleepiness or drowsiness is generally described as uncommon or rare in the official side effect listings. This is due to the drug's chemical structure, which is intended to limit its passage across the blood-brain barrier and minimize effects on the central nervous system (CNS).

Q: Can Butylscopolamine be taken with common over-the-counter pain relievers?

A: Regulatory patient information confirms that Butylscopolamine can generally be taken at the same time as common over-the-counter pain relievers. Examples of painkillers cited in patient information that can be taken with this medicine include paracetamol (acetaminophen) and ibuprofen.

Q: Is it generally described as safe to consume alcohol while using this medicine?

A: Official information suggests that consuming alcohol while taking this medication may increase the potential for side effects. This is primarily noted as increasing the chance of effects such as drowsiness or dizziness.

Q: How long do the effects of Butylscopolamine usually last in the body?

A: The duration of the medicine’s action is related to how quickly the body processes it. Pharmacokinetic data indicates that the elimination half-life (the time it takes for half the medicine to be removed from the bloodstream) is approximately 5 hours.

Q: Is Butylscopolamine available without a prescription in certain countries?

A: Yes, its regulatory classification varies internationally. This medicine is available worldwide both as a prescription drug and as an over-the-counter (OTC) medicine in many countries, depending on the local health authority's determination.

Q: Does Butylscopolamine typically affect a person's blood pressure?

A: One potential adverse effect listed, particularly with the injectable form, is reduced blood pressure (hypotension). Official documents indicate that caution and monitoring are advised when administering the medicine to patients with pre-existing heart conditions or high blood pressure (hypertension).

Q: What is the general guidance if a dose of Butylscopolamine is missed?

A: Official patient information advises to skip the missed dose and take the next dose at the usual scheduled time. Patient guidance specifies that two doses should not be taken at the same time.

Q: Does Butylscopolamine primarily affect the muscular activity of the stomach or the intestines?

A: The drug is designed to act on the smooth muscle cells throughout the digestive tract to relieve spasms. This includes the muscles of the stomach, small intestine, and colon, as well as the biliary and urinary tracts.

Q: What research evidence exists for the use of Butylscopolamine in conditions like Irritable Bowel Syndrome (IBS)?

A: Official patient information mentions the use of this medicine for symptoms related to Irritable Bowel Syndrome (IBS). Official patient information mentions the use of the medicine for IBS symptoms, noting that this is typically for cases that have been formally diagnosed.

Q: Does Butylscopolamine generally impact the ability to drive or operate machinery?

A: Regulatory warnings advise caution and recommend that individuals should avoid driving or operating machinery if side effects such as blurred vision, dizziness, or drowsiness occur, until those symptoms have fully resolved.

Q: Are there known interactions between Butylscopolamine and common vitamin or herbal supplements?

A: Regulatory guidance indicates there is generally insufficient information to confirm whether complementary or herbal remedies are safe to take with Butylscopolamine. Official guidance emphasizes the importance of informing a doctor or pharmacist about any supplements being used.

Q: What is the difference between Butylscopolamine and other common antimuscarinic drugs?

A: The key difference lies in its chemical structure as a quaternary ammonium compound. This structure prevents it from easily crossing the blood-brain barrier (the protective layer around the brain). This results in its actions being focused almost entirely on the peripheral nervous system, unlike some other antimuscarinic drugs.

Q: Is Butylscopolamine approved for relieving pain related to gallstones (biliary colic)?

A: Yes, official drug information and clinical resources list both biliary colic (pain related to gallstones) and renal colic (pain related to kidney stones) as conditions for which this antispasmodic medicine is used.

Q: What is the significance of the chemical component 'bromide' in Hyoscine Butylbromide?

A: The term 'bromide' refers to the counter-ion of the drug's chemical salt structure. This structure is essential to make the molecule highly charged and polar. This high polarity helps prevent the drug from crossing the blood-brain barrier, which keeps its muscle-relaxing effects targeted and peripheral.

Q: Does Butylscopolamine interact with medication used to treat Parkinson's disease?

A: Yes, official interaction listings note that Butylscopolamine can interact with certain medications used for Parkinson's disease, specifically amantadine. Combining these medicines can increase the risk of experiencing anticholinergic side effects.

Q: What is the difference between an 'antispasmodic' and an 'anticholinergic' drug?

A: The official classification states Butylscopolamine is an anticholinergic agent, which describes its mechanism of action at the nerve level (blocking acetylcholine). It is classified functionally as an antispasmodic drug, which describes the desired functional effect of relaxing smooth muscles to reduce spasms and pain.

Storage and Disposal Requirements

The storage and disposal instructions for both Butylscopolamine (Hyoscine butylbromide) and the Scopolamine transdermal system are strictly defined by regulatory labeling to maintain stability and prevent accidental exposure.

• Temperature and Protection: Scopolamine patches must be stored at controlled room temperature (20 C to 25 C) in their sealed pouch. Butylscopolamine tablets should be stored at or below 30 C, protected from light and moisture, and kept in the original container.

• Child Safety: All forms must be stored out of the sight and reach of children.

• Disposal Protocol: Used Scopolamine patches must be immediately folded in half (adhesive sides together) and discarded in household trash. Unused or expired Butylscopolamine should not be disposed of in wastewater and must be managed according to local regulations or returned to a pharmacist.